We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+7.3%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$1.5B
AUM Growth
+$79.1M
Cap. Flow
+$24.7M
Cap. Flow %
1.64%
Top 10 Hldgs %
31.43%
Holding
99
New
7
Increased
27
Reduced
26
Closed
7

Top Buys

Rank Stock Value
1
BSX icon
Boston Scientific
BSX
+$14.3M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$13.9M
3
INSP icon
Inspire Medical Systems
INSP
+$11.3M
4
DHR icon
Danaher
DHR
+$11.2M
5
OLMA icon
Olema Pharmaceuticals
OLMA
+$10.4M

Top Sells

Rank Stock Value
1
ABT icon
Abbott
ABT
+$13.6M
2
TMO icon
Thermo Fisher Scientific
TMO
+$9.99M
3
ELV icon
Elevance Health
ELV
+$9.26M
4
BIIB icon
Biogen
BIIB
+$9M
5
RVNC
Revance Therapeutics, Inc.
RVNC
+$8.91M

Sector Composition

Rank Sector Weight
1 Healthcare 97.82%
2 Industrials 1.29%
3 Technology 0.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BHVN
26
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$20.7M 1.38%
150,000
+15,000
+11% +$1.91M
APLS
27
DELISTED
Apellis Pharmaceuticals
APLS
$20.6M 1.37%
430,000
-131,269
-23% -$5.17M
ITCI
28
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$20.3M 1.35%
390,000
-39,728
-9% -$1.67M
GILD icon
29
Gilead Sciences
GILD
$165B
$20.2M 1.34%
275,000
-25,000
-8% -$1.72M
GH icon
30
Guardant Health
GH
$22.8B
$20M 1.33%
200,000
-5,000
-2% -$517K
SGEN
31
DELISTED
Seagen Inc. Common Stock
SGEN
$20M 1.33%
127,000
-8,000
-6% -$1.34M
ABMD
32
DELISTED
Abiomed Inc
ABMD
$18.8M 1.25%
52,000
-18,000
-26% -$6.08M
XNCR icon
33
Xencor
XNCR
$1.59B
$18.3M 1.22%
450,000
-57,002
-11% -$2.16M
AXNX
34
DELISTED
Axonics, Inc. Common Stock
AXNX
$17.7M 1.18%
315,000
+25,000
+9% +$1.53M
THC icon
35
Tenet Healthcare
THC
$21B
$17.2M 1.14%
210,000
+30,000
+17% +$2.19M
VEEV icon
36
Veeva Systems
VEEV
$38.1B
$15.6M 1.04%
60,000
– –
PRVA icon
37
Privia Health
PRVA
$2.83B
$15.4M 1.02%
580,000
+340,000
+142% +$8.48M
HCA icon
38
HCA Healthcare
HCA
$89.3B
$15.2M 1.01%
59,000
-16,000
-21% -$3.92M
ISRG icon
39
Intuitive Surgical
ISRG
$138B
$14.5M 0.97%
40,000
-20,000
-33% -$6.88M
ABT icon
40
Abbott
ABT
$188B
$14.1M 0.94%
100,000
-106,000
-51% -$13.6M
RCM
41
DELISTED
R1 RCM Inc. Common Stock
RCM
$13.9M 0.92%
550,000
– –
NKTR icon
42
Nektar Therapeutics
NKTR
$2.52B
$13.3M 0.88%
63,333
– –
EW icon
43
Edwards Lifesciences
EW
$53.3B
$13.1M 0.87%
100,000
-5,000
-5% -$583K
NBIX icon
44
Neurocrine Biosciences
NBIX
$16.7B
$12.8M 0.85%
151,100
+56,100
+59% +$5.16M
DHR icon
45
Danaher
DHR
$145B
$11.8M 0.79%
+40,608
New +$11.2M
TDOC icon
46
Teladoc Health
TDOC
$1.29B
$11.8M 0.78%
125,000
-25,000
-17% -$2.99M
IOVA icon
47
Iovance Biotherapeutics
IOVA
$2.89B
$11.7M 0.77%
600,000
+280,000
+88% +$6.16M
ZBH icon
48
Zimmer Biomet
ZBH
$18.5B
$11.5M 0.77%
92,700
-30,900
-25% -$4.04M
IMGN
49
DELISTED
Immunogen Inc
IMGN
$11.2M 0.74%
1,500,000
+281,150
+23% +$1.75M
INSP icon
50
Inspire Medical Systems
INSP
$1.74B
$10.7M 0.71%
+46,373
New +$11.3M
1
2
3 4

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q4 2021 Portfolio in Review

As of Q4 2021, Rhenman & Partners Asset Management held 99 positions worth $1.5B, up 5.6% from $1.42B the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Rhenman & Partners Asset Management's Q4 2021 filing shows 7 new, 27 increased, 26 reduced and 7 closed positions. Its largest new stake was Inspire Medical Systems: 46,373 shares worth $10.7M. The largest sale was Abbott, an estimated $13.6M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Industrials and Technology.

  • Rhenman & Partners Asset Management's largest Q4 2021 buy was Inspire Medical Systems: 46,373 shares worth $10.7M.
  • Rhenman & Partners Asset Management added most to Boston Scientific in Q4 2021, an estimated $14.3M increase.
  • Rhenman & Partners Asset Management's biggest Q4 2021 reduction was Abbott, cutting an estimated $13.6M.
  • Rhenman & Partners Asset Management fully exited Revance Therapeutics, Inc. in Q4 2021, selling an estimated $8.91M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 31% of its $1.5B portfolio in Q4 2021.
  • Rhenman & Partners Asset Management opened 7 new positions and closed 7 in Q4 2021.
  • Rhenman & Partners Asset Management's portfolio value rose 5.6% quarter-over-quarter to $1.5B.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2021, filed 11 Feb 2022.